2021
Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
Doyle HA, Gee RJ, Masters TD, Gee CR, Booth CJ, Peterson-Roth E, Koski RA, Helfand SC, Price L, Bascombe D, Jackson D, Ho R, Post GR, Mamula MJ. Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. Translational Oncology 2021, 14: 101205. PMID: 34419682, PMCID: PMC8379704, DOI: 10.1016/j.tranon.2021.101205.Peer-Reviewed Original ResearchEpidermal growth factor receptorAnti-tumor immunityMonoclonal antibody therapyEGFR/HER2Antibody therapyPhase I/II open label studyCanine cancersHuman epidermal growth factor receptorImmune modifying therapiesOpen-label studyCD8 T cellsHuman cancersStandard cancer therapiesProgression of diseaseInhibited tumor growthSpontaneous canine cancersGrowth factor receptorMonoclonal therapyCheckpoint inhibitorsModifying therapiesIgG depositionObjective responseVaccine therapyMetastatic sitesAntigen response
2018
Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3
Doyle HA, Koski RA, Bonafé N, Bruck RA, Tagliatela SM, Gee RJ, Mamula MJ. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3. Cancer Immunology, Immunotherapy 2018, 67: 1559-1569. PMID: 30056598, PMCID: PMC7268894, DOI: 10.1007/s00262-018-2218-9.Peer-Reviewed Original ResearchConceptsAntibody-dependent cell-mediated cytotoxicityEpidermal growth factor receptorAnti-tumor immunityMonoclonal antibody treatmentAntibody treatmentImmune serumElicit anti-tumor immunityAnti-EGFR monoclonal antibodiesHuman epidermal growth factor receptorPeptide-based vaccinationCross-reactive immunityT cell responsesCell-mediated cytotoxicityAnti-tumor antibodiesNatural anti-tumor antibodiesMDA-MB-453Tumor cell killingErbB family membersGrowth factor receptorPeptide vaccinationStandard chemotherapyImmune toleranceCurrent treatmentDrug infusionRadiation therapy